These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
337 related articles for article (PubMed ID: 33030673)
1. Tideglusib attenuates growth of neuroblastoma cancer stem/progenitor cells in vitro and in vivo by specifically targeting GSK-3β. Bahmad HF; Chalhoub RM; Harati H; Bou-Gharios J; Assi S; Ballout F; Monzer A; Msheik H; Araji T; Elajami MK; Ghanem P; Chamaa F; Kadara H; Abou-Antoun T; Daoud G; Fares Y; Abou-Kheir W Pharmacol Rep; 2021 Feb; 73(1):211-226. PubMed ID: 33030673 [TBL] [Abstract][Full Text] [Related]
2. The potential use of tideglusib as an adjuvant radio-therapeutic treatment for glioblastoma multiforme cancer stem-like cells. Bou-Gharios J; Assi S; Bahmad HF; Kharroubi H; Araji T; Chalhoub RM; Ballout F; Harati H; Fares Y; Abou-Kheir W Pharmacol Rep; 2021 Feb; 73(1):227-239. PubMed ID: 33140310 [TBL] [Abstract][Full Text] [Related]
3. Tideglusib suppresses stem-cell-like features and progression of osteosarcoma by inhibiting GSK-3β/NOTCH1 signaling. Wei D; Zhu X; Li S; Liu G; Wang Y; Wang W; Zhang Q; Jiang S Biochem Biophys Res Commun; 2021 May; 554():206-213. PubMed ID: 33813076 [TBL] [Abstract][Full Text] [Related]
4. Antiproliferative and apoptotic effect of LY2090314, a GSK-3 inhibitor, in neuroblastoma in vitro. Kunnimalaiyaan S; Schwartz VK; Jackson IA; Clark Gamblin T; Kunnimalaiyaan M BMC Cancer; 2018 May; 18(1):560. PubMed ID: 29751783 [TBL] [Abstract][Full Text] [Related]
5. Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma. Bayat Mokhtari R; Baluch N; Ka Hon Tsui M; Kumar S; S Homayouni T; Aitken K; Das B; Baruchel S; Yeger H BMC Cancer; 2017 Feb; 17(1):156. PubMed ID: 28235409 [TBL] [Abstract][Full Text] [Related]
6. GSK-3β inhibition promotes cell death, apoptosis, and in vivo tumor growth delay in neuroblastoma Neuro-2A cell line. Dickey A; Schleicher S; Leahy K; Hu R; Hallahan D; Thotala DK J Neurooncol; 2011 Aug; 104(1):145-53. PubMed ID: 21161565 [TBL] [Abstract][Full Text] [Related]
7. XAV939 inhibits the stemness and migration of neuroblastoma cancer stem cells via repression of tankyrase 1. Tian X; Hou W; Bai S; Fan J; Tong H; Xu H Int J Oncol; 2014 Jul; 45(1):121-8. PubMed ID: 24789807 [TBL] [Abstract][Full Text] [Related]
8. Glycogen synthase kinase-3β inhibition depletes the population of prostate cancer stem/progenitor-like cells and attenuates metastatic growth. Kroon J; in 't Veld LS; Buijs JT; Cheung H; van der Horst G; van der Pluijm G Oncotarget; 2014 Oct; 5(19):8986-94. PubMed ID: 25344861 [TBL] [Abstract][Full Text] [Related]
10. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor. Capurro V; Lanfranco M; Summa M; Porceddu PF; Ciampoli M; Margaroli N; Durando L; Garrone B; Ombrato R; Tongiani S; Reggiani A Biomed Pharmacother; 2020 Aug; 128():110249. PubMed ID: 32470749 [TBL] [Abstract][Full Text] [Related]
11. Proteins of the Wnt signaling pathway as targets for the regulation of CD133+ cancer stem cells in glioblastoma. Shevchenko V; Arnotskaya N; Korneyko M; Zaytsev S; Khotimchenko Y; Sharma H; Bryukhovetskiy I Oncol Rep; 2019 May; 41(5):3080-3088. PubMed ID: 30864699 [TBL] [Abstract][Full Text] [Related]
12. POTEE stimulates the proliferation of pancreatic cancer by activating the PI3K/Akt/GSK-3β/β-catenin signaling. Hao Q; Gao L; Niu W; Chen L; Zhang P; Chen Z Biofactors; 2020 Jul; 46(4):685-692. PubMed ID: 32589786 [TBL] [Abstract][Full Text] [Related]
13. Inactivation of glycogen synthase kinase-3beta contributes to brain-derived neutrophic factor/TrkB-induced resistance to chemotherapy in neuroblastoma cells. Li Z; Tan F; Thiele CJ Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3113-21. PubMed ID: 18089706 [TBL] [Abstract][Full Text] [Related]
14. 9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma. Ugolkov AV; Bondarenko GI; Dubrovskyi O; Berbegall AP; Navarro S; Noguera R; O'Halloran TV; Hendrix MJ; Giles FJ; Mazar AP Anticancer Drugs; 2018 Sep; 29(8):717-724. PubMed ID: 29846250 [TBL] [Abstract][Full Text] [Related]
15. GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals. Abrams SL; Akula SM; Meher AK; Steelman LS; Gizak A; Duda P; Rakus D; Martelli AM; Ratti S; Cocco L; Montalto G; Cervello M; Ruvolo P; Libra M; Falzone L; Candido S; McCubrey JA Cells; 2021 Apr; 10(4):. PubMed ID: 33917370 [TBL] [Abstract][Full Text] [Related]
16. Dual-Blocking of PI3K and mTOR Improves Chemotherapeutic Effects on SW620 Human Colorectal Cancer Stem Cells by Inducing Differentiation. Kim MJ; Koo JE; Han GY; Kim B; Lee YS; Ahn C; Kim CW J Korean Med Sci; 2016 Mar; 31(3):360-70. PubMed ID: 26955235 [TBL] [Abstract][Full Text] [Related]
17. Effects of the GSK-3β inhibitor (2Z,3E)-6-bromoindirubin-3'-oxime upon ovarian cancer cells. Yu AS; Zhao L Tumour Biol; 2016 Apr; 37(4):4857-64. PubMed ID: 26526575 [TBL] [Abstract][Full Text] [Related]
18. PI3K Inhibitor Combined With Chemotherapy Can Enhance the Apoptosis of Neuroblastoma Cells In Vitro and In Vivo. Geng X; Xie L; Xing H Technol Cancer Res Treat; 2016 Oct; 15(5):716-22. PubMed ID: 26224681 [TBL] [Abstract][Full Text] [Related]
19. Tideglusib induces apoptosis in human neuroblastoma IMR32 cells, provoking sub-G0/G1 accumulation and ROS generation. Mathuram TL; Ravikumar V; Reece LM; Karthik S; Sasikumar CS; Cherian KM Environ Toxicol Pharmacol; 2016 Sep; 46():194-205. PubMed ID: 27490211 [TBL] [Abstract][Full Text] [Related]
20. Mechanism of zinc-induced phosphorylation of p70 S6 kinase and glycogen synthase kinase 3beta in SH-SY5Y neuroblastoma cells. An WL; Bjorkdahl C; Liu R; Cowburn RF; Winblad B; Pei JJ J Neurochem; 2005 Mar; 92(5):1104-15. PubMed ID: 15715661 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]